Spruce Biosciences, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $2.00K.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $22.00K, a 57.14% increase year-over-year.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $3.00K.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $14.00K, a 80.00% decline year-over-year.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $25.00K, a 62.12% decline from fiscal 2024.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $66.00K, a 60.95% decline from fiscal 2023.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $169.00K, a 122.37% increase from fiscal 2022.
- Spruce Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $76.00K, a 43.28% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $2.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $25.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $3.00K 10-Q · filed 2025-11-10 | |
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $66.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $52.00K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $169.00K 10-K · filed 2025-04-15 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $99.00K 10-Q · filed 2024-08-12 | |
| 2022-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $76.00K 10-K · filed 2024-03-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $38.00K 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $134.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $96.00K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |